SeqLL Inc

For the period ended Dec 31, 2023. Filed Apr 10, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 10, 2024

CIRC$0.18-13.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits and Financial Statement Schedules

Incorporation by Reference
Exhibit Number	Description of Exhibits	Form	Filing Date	Exhibit Number
2.1	Agreement and Plan of Reorganization	8-K	5/31/23	2.1
2.2	Amendment No. 1 to Agreement and Plan of Reorganization effective as of June 22, 2023	8-K	6/23/23	2.2
2.3	Amendment No. 2 to Agreement and Plan of Reorganization effective as of October 5, 2023	S-1/A	10/18/23	2.3
2.4	Amendment No. 3 to Agreement and Plan of Reorganization effective as of October 17, 2023	S-1/A	10/18/23	2.4
2.5	Amendment No. 4 to Agreement and Plan of Reorganization effective as of November 3, 2023	S-1/A	11/7/23	2.5
2.6	Amendment No. 5 to Agreement and Plan of Reorganization effective as of January 16, 2024	8-K	1/18/24	2.1
3.1	Amended and Restated Certificate of Incorporation	8-K	8/31/21	3.1
3.2	Amended and Restated Bylaws	8-K	8/31/21	3.2
4.1	Description of Securities	10-K	3/23/22	4.1
4.2	Specimen common stock certificate	S-1/A	5/22/19	4.1
4.3	Warrant Agency Agreement dated as of August 31, 2021 between SeqLL Inc. and VSTOCK Transfer LLC	8-K	8/31/21	10.1
4.4	Form of Common Stock Purchase Warrant	S-1/A	8/16/21	4.6
10.1#	Amended and Restated 2014 Equity Incentive Plan	S-1	3/31/21	10.1
10.2	License Agreement dated March 15, 2013 between SeqLL, LLC and Helicos Biosciences Corporation	S-1	4/23/19	10.2
10.3	Sub-License Agreement dated March 15, 2013 between SeqLL, LLC and Helicos Biosciences Corporation	S-1	4/23/19	10.3
10.4	Asset Purchase Agreement dated as of May 29, 2023	8-K	5/31/23	10.1
10.13	Investor Rights Agreement dated as of September 30, 2018	S-1/A	5/28/21	10.13
22*	Subsidiaries of the Registrant
23*	Consent of Wolf & Company, P.C.
31.1*	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 302 of The Sarbanes-Oxley Act of 2002
31.2*	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 302 of The Sarbanes-Oxley Act of 2002
32.1*	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002
32.2*	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith.

#	Indicates a management contract or compensatory plan.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.